|
Delayed
OTC Markets
14:24:12 2026-10-07 EDT
|
5-day change | 1st Jan Change | ||
| 6.000 USD | -0.41% |
|
-6.10% | -2.45% |
Company Valuation: Interpace Biosciences, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 12.69 | 31.18 | 4.437 | 4.693 | 11.87 | 5.448 |
| Change | - | 145.72% | -85.77% | 5.76% | 152.98% | -54.11% |
| Enterprise Value (EV) 1 | 14.8 | 41.84 | 15.7 | 12.39 | 16.27 | 4.126 |
| Change | - | 182.66% | -62.47% | -21.1% | 31.32% | -74.64% |
| P/E | -0.43x | -2.06x | -0.2x | 6.03x | 6.84x | 1.39x |
| PBR | -0.44x | -0.74x | -0.07x | -0.08x | -5.36x | 0.25x |
| PEG | - | 0x | -0x | -0x | 0x | 0x |
| Capitalization / Revenue | 0.39x | 0.75x | 0.14x | 0.12x | 0.25x | 0.14x |
| EV / Revenue | 0.46x | 1.01x | 0.49x | 0.31x | 0.35x | 0.11x |
| EV / EBITDA | -0.7x | -6.28x | -12.3x | 3.23x | 1.93x | 0.79x |
| EV / EBIT | -0.56x | -3.56x | -4.09x | 4.41x | 2.01x | 0.86x |
| EV / FCF | -2.21x | -25.8x | -15.1x | 2.93x | 11.5x | 0.81x |
| FCF Yield | -45.2% | -3.87% | -6.64% | 34.1% | 8.66% | 123% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -36.61 | -18.09 | -25.91 | 0.8948 | 1.972 | 4.426 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 32.4 | 41.31 | 31.84 | 40.21 | 46.93 | 38.73 |
| EBITDA 1 | -21.15 | -6.663 | -1.28 | 3.837 | 8.408 | 5.209 |
| EBIT 1 | -26.56 | -11.74 | -3.84 | 2.811 | 8.108 | 4.784 |
| Net income 1 | -26.45 | -14.94 | -21.96 | 0.802 | 6.702 | 24.58 |
| Net Debt 1 | 2.11 | 10.65 | 11.26 | 7.694 | 4.395 | -1.322 |
| Reference price 2 | 15.700 | 37.350 | 5.200 | 5.400 | 13.488 | 6.151 |
| Nbr of stocks (in thousands) | 808 | 835 | 853 | 869 | 880 | 886 |
| Announcement Date | 4/1/21 | 3/31/22 | 3/27/23 | 4/1/24 | 3/31/25 | 3/30/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 33.25M | |
| 12.77x | 0.39x | 8.22x | 3.03% | 112B | |
| 15.03x | 1.86x | 9.3x | 0.7% | 96.35B | |
| -276.43x | 18.99x | -322.89x | -.--% | 56.33B | |
| 12.69x | 1.42x | 8.57x | 2.81% | 26.23B | |
| 22.55x | 2.08x | 11.9x | 0.93% | 25.48B | |
| 22.7x | 2.54x | 12.88x | 1.43% | 25.48B | |
| 31.28x | 5.67x | 23.55x | 2.23% | 21.32B | |
| 7.91x | 1.43x | 6.48x | -.--% | 20.98B | |
| 20.94x | 1.86x | 9.37x | 3.33% | 19.83B | |
| Average | -14.50x | 4.03x | -25.85x | 1.61% | 40.43B | |
| Weighted average by Cap. | -24.62x | 4.05x | -36.33x | 1.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IDXG Stock
- Valuation Interpace Biosciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
